| (EUR) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 218.25M | — |
| Operating expense | — | — |
| Net income | 78.39M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, BO1.F returned +13.5% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +27.1% |
| 1 year | +13.5% |
| 5 years | -38.8% |
| 10 years | +126.5% |
| All-time high | €34.50 (Aug 2000) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what €1,000 in BO1.F would be worth today ›No. BioCryst Pharmaceuticals, Inc. has not paid a dividend in the past 12 months.
BioCryst Pharmaceuticals, Inc. is part of the Healthcare sector.
BioCryst Pharmaceuticals, Inc. has a market cap of 2.09B EUR, based on the latest quote.
BioCryst Pharmaceuticals, Inc. is expected to report earnings around Nov 2, 2026. That date is an estimate and has not been confirmed by the company.
